Table 1 Characteristics of the randomized controlled trials included in the systematic review and meta-analysis
Study/Country | SSRI/dosage | Comparator | N (% male) | Mean age (age range or SD) | Duration of study | Mean duration of PD (SD) | Hoehn and Yahr stage mean (SD) | Depression Scale | Treatment responders (response rate) | Dropouts |
|---|---|---|---|---|---|---|---|---|---|---|
Devos et al. (2008)/France [22] | citalopram (20 mg/day) | 1. placebo 2. desipramine (75 mg/day) | 48 (NA) | 61.8 (56-68) | 4 weeks | 8 years | NA | MADRS | citalopram: 8/15 (53%) placebo: 4/16 (25%) desipramine: 11/17 (65%) | 3 |
Wermuth et al. (1998)/Denmark [21] | citalopram (10-20 mg/day) | placebo | 37 (43%) | 64 (44-79) | 6 weeks (acute phase) | NA | I-III (range) | HDRS | citalopram: 2/18 (11%) placebo: 3/19 (16%) | 7 |
Antonini et al. (2006)/Italy [19] | sertraline (50 mg/day) | amitriptyline (25 mg/day) | 31 (45%) | S: 71.8 (6.5) a C: 68.5 (6.6) a | 12 weeks | S: 7.5 years (3.4) a C: 7.3 years (4.5) a | S: 2.0 ( 0.7) a C: 2.4 (0.6) a | HDRS | sertraline: 10/16 (63%) amitriptyline: 8/15 (53%) | 8 |
Barone et al. (2006)/Italy [20] | sertraline (mean dose: 48.1 ± 5.9 mg/day) | pramipexole (mean dose: 3.24 ± 1.3 mg/day) | 67 (52%) | S: 68.1 (6.5) C: 64.8 (8.3) | 12 weeks | NA | S: 2.5 (median) C: 2 (median) | HDRS | sertraline: 16/34 (47%) pramipexole: 23/33 (70%) | 8 |
Leentjens et al. (2003)/The Netherlands [14] | sertraline (25-100 mg/day) | placebo | 12 (67%) | 67 (7.8) | 10 weeks | NA | I-IV (range) | MADRS | sertraline: 3/6 (50%) placebo: 4/6 (67%) | 0 |
Fregni et al. (2004)/USA [25] | fluoxetine (20 mg/day) | rTMS (15 Hz) | 43 (62%) a | S: 66.0 (8.5) a C: 65.3 (7.8) a | 8 weeks | NA | S: 2.1 (1.2) a C: 2.1 (1.2) a | HDRS | fluoxetine: 9/21 (43%) rTMS: 9/22 (41%) | 1 |
Serrano-Duenas (2002)/Ecuador [23] | fluoxetine (mean dose: 27.3 mg/day) | amitriptyline (mean dose: 35.2 mg/day) | 77 (56%) | 68.2 (4.5) | 12 months | 6.9 years (0.8) | II | HDRS | NA | 19 |
Avila et al. (2003)/Spain [24] | fluoxetine (mean dose: 25 mg/day) | nefazodone (mean dose: 200 mg/day) | 16 (44%) | 70.4 (59-78) | 12 weeks | 5 years | S: 2.6 (0.8) C: 2.3 (0.5) | BDI | NA | 3 |
Menza et al. (2008)/USA [26] | paroxetine CR (mean dose: 28.4 mg/day) | 1. placebo 2. nortriptyline (mean dose: 48.5 mg/day) | 52 (52%) | 62.2 (8.7) | 8 weeks | 6.6 years | 2.2 | HDRS | paroxetine: 2/18 (11%) placebo: 4/17 (24%) nortriptyline 9/17 (53%) | 18 |
Rabey et al. (1996)/Israel [27] | fluvoxamine (mean dose: 78 mg/day) | amitriptyline (mean dose: 69 mg/day) | 47 (NA) | 75 (NA) | 16 weeks | 7 years | NA | HDRS | fluvoxamine: 12/20 (60%) amitriptyline: 15/27 (56%) | 20 |